The challenge with curing the Human Immunodeficiency Virus (HIV) is that it tends to hide dormant in cells, evading the body’s natural immune system as well as some therapies. A new study uses novel ...

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...

HIV prevention drug Lenacapavir, which has been tested in South Africa during clinical trials, will be made available in the country in 2026 for high-risk groups.

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they explained how U.S.-funded ...

Addressing the question of whether and how immune cells (macrophages) in the central nervous system (CNS) traffic out, ...

In July 2024, we published a story with the headline: "One of the 7 people cured of HIV tells his story. Can his cure work for others." This summer, at the International AIDS Society conference, came ...

More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...

WHO has sounded alarm over a sharp spike in HIV cases in the Philippines, Fiji and Papua New Guinea, urging urgent prevention ...

Over the next week, we'll be looking back at some of our favorite Goats and Soda stories to see "whatever happened to ..." In July 2024, we published a story with the headline: "One of the 7 people ...